Variable | ASP−n (%) | ASP+n (%) | P value |
Median age in months (IQR) | 26 (93) | 24 (65) | 0.485 |
Gender male | 150 (62.5) | 86 (63) | |
PRISM-III | 5.68 ± 5.14 | 7.4 ± 6.3 | |
Diagnosis | |||
Respiratory system diseases | 27 (20) | 31 (24.4) | > 0.05 |
Cardiovascular system diseases | 12 (9) | 13 (10.2) | |
Neurological diseases | 25 (18.5) | 16 (12.6) | |
Surgical disease | 58 (43) | 41 (32.3) | |
Miscellaneous | 13 (9.5) | 26 (20.5) | |
Empirical | 57 (42) | 60 (47.4) | |
Prophylaxis | 58 (43) | 55 (43.2) | |
Therapeutic | 20 (15) | 12 (9.4) | |
Intervention | None | 29 (22.6) | |
Dose | None | 11 (8.5) | |
Choice | None | 15 (11.7) | |
Duration/stop | 15 % | 6 (4.6) | |
Monitor/interaction | None | 6 (4.6) | |
DOT | 1937 | 651 | |
<2 days | 8 (6) | 57 (45) | |
>5 days | 87 (64) | 8 (6) | |
Patient’s days (PtD) | 557 | 492 | |
DOT/1000 PtD | 1937/0.557=3477 | 651/0.492=1323 | <0.0001 |
DOT-vanco | 346 | 174 | 0.002 |
DOT-mero | 323 | 154 | 0.001 |
DOT-colis | 115 | 100 | 0.70 |
DOT-ceftri | 532 | 186 | 0.00 |
Cost in PKR | 2 212 468 | 929 568 | 0.00 |
Mortality (%) | 22 (16.2) | 20 (15.7) |
ASP, antibiotic stewardship programme; CVS, cerebrovascular disease; DOT, days of therapy; PKR, Pakistani Rupee; Pt D, patient days; PRISM, Paediatric Risk of Mortality.